# OnCo record nct07714668 (trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/trials/nct07714668/>
  a schema:MedicalTrial ;
  onco:kind "trial" ;
  schema:identifier "nct07714668", "NCT07714668" ;
  schema:name "A Clinical Study of SYS6041 Combination Therapy for Recurrent Ovarian Cancer"@en ;
  schema:description "A phase 2 trial of Farletuzumab-exatecan, Bevacizumab, Carboplatin in ovarian cancer, run by CSPC Megalith Biopharmaceutical Co.,Ltd., now recruiting."@en ;
  schema:url <https://onco.cc/trials/nct07714668/> ;
  schema:dateModified "2026-09-16"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/study/NCT07714668> ;
  onco:status "recruiting" ;
  onco:tag "ctgov-ingest" ;
  onco:phase "2" ;
  schema:startDate "2026-08-13" ;
  onco:cancers <https://onco.cc/cancers/ovarian/> ;
  onco:drugs <https://onco.cc/drugs/farletuzumab-exatecan/>, <https://onco.cc/drugs/bevacizumab/>, <https://onco.cc/drugs/carboplatin/>, <https://onco.cc/drugs/paclitaxel/> ;
  onco:companies <https://onco.cc/companies/cspc/> .